Adjuvant donafenib for hepatocellular carcinoma patients at high-risk of recurrence after radical resection: a real-world experience

Background: Adjuvant therapy is used to reduce the risk of hepatocellular carcinoma (HCC) recurrence and improve patient prognosis. Exploration of treatment strategies that are both efficacious and safe has been extensively performed in the recent years. Although donafenib has demonstrated good effi...

Descripció completa

Dades bibliogràfiques

Autors principals:	Shenyu Zhang, Guibin Yang, Ruipeng Song, Wei Wang, Fanzheng Meng, Dalong Yin, Jiabei Wang, Shugeng Zhang, Wei Cai, Yao Liu, Dayong Luo, Jizhou Wang, Lianxin Liu
Format:	Artigo
Idioma:	Inglês
Publicat:	SAGE Publishing 2024-06-01
Col·lecció:	Therapeutic Advances in Medical Oncology
Accés en línia:	https://doi.org/10.1177/17588359241258394
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!